東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

The use of proteomic technologies to...

Schwegler, Elizabeth Ellen.

FindBook

Google Book

Amazon

博客來

The use of proteomic technologies to identify serum glycoproteins for the early detection of liver and prostate cancers.

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	The use of proteomic technologies to identify serum glycoproteins for the early detection of liver and prostate cancers./
作者:	Schwegler, Elizabeth Ellen.
面頁冊數:	155 p.
附註:	Adviser: Richard Drake.
Contained By:	Dissertation Abstracts International67-12B.
標題:	Biology, Molecular. -
電子資源:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3246902

The use of proteomic technologies to identify serum glycoproteins for the early detection of liver and prostate cancers.
Schwegler, Elizabeth Ellen.

The use of proteomic technologies to identify serum glycoproteins for the early detection of liver and prostate cancers. - 155 p.

Adviser: Richard Drake.

Thesis (Ph.D.)--Old Dominion University, 2006.

The application of proteomic technologies to identify serum glycoproteins is an emerging technique to identify new biomarkers indicative of disease severity. Many of these newly evolving protein-profiling methodologies have evolved from previous global protein expression profiling studies such as those involving SELDI-TOF-MS technologies. Though the SELDI approach could distinguish disease from normal by utilizing protein patterns as shown herein with the HCC study of chapter II, it was unable to offer sequence information on the selected peaks, and did not have the ability to analyze the entire dynamic range of the serum/plasma proteome. To address these deficiencies, new strategies that incorporate the use of differential lectin-based glycoprotein capture and targeted immuno-based assays have been developed. The carbohydrate binding specificities of different lectins offers a biological affinity approach that both complements existing mass spectrometer capabilities and retains automated throughput options. A prostate cancer study using disease stratified samples is utilized herein to determine whether lectin capture can identify glycoproteins, which are indicative of different stages of prostate disease. By utilizing upfront lectin fractionation we show here evidence of glycoproteins and glycoprotein isoforms, which are specific to cancer progression. In addition, the incorporation of lectin fractionation followed by albumin depletion allows for a more in depth analysis of the entire dynamic range of the human serum and plasma proteome. Taken together we believe this approach is an attractive strategy for the discovery of proteins indicative of the early detection of liver and prostate cancers.Subjects--Topical Terms:

1017719
Biology, Molecular.

The use of proteomic technologies to identify serum glycoproteins for the early detection of liver and prostate cancers.
LDR:02617nam 2200265 a 45 001 970686
005 20110921
008 110921s2006 eng d
035 $a (UMI)AAI3246902
035 $a AAI3246902
040 $a UMI $c UMI
100 1 $a Schwegler, Elizabeth Ellen. $3 1294722
245 1 4 $a The use of proteomic technologies to identify serum glycoproteins for the early detection of liver and prostate cancers.
300 $a 155 p.
500 $a Adviser: Richard Drake.
500 $a Source: Dissertation Abstracts International, Volume: 67-12, Section: B, page: 6902.
502 $a Thesis (Ph.D.)--Old Dominion University, 2006.
520 $a The application of proteomic technologies to identify serum glycoproteins is an emerging technique to identify new biomarkers indicative of disease severity. Many of these newly evolving protein-profiling methodologies have evolved from previous global protein expression profiling studies such as those involving SELDI-TOF-MS technologies. Though the SELDI approach could distinguish disease from normal by utilizing protein patterns as shown herein with the HCC study of chapter II, it was unable to offer sequence information on the selected peaks, and did not have the ability to analyze the entire dynamic range of the serum/plasma proteome. To address these deficiencies, new strategies that incorporate the use of differential lectin-based glycoprotein capture and targeted immuno-based assays have been developed. The carbohydrate binding specificities of different lectins offers a biological affinity approach that both complements existing mass spectrometer capabilities and retains automated throughput options. A prostate cancer study using disease stratified samples is utilized herein to determine whether lectin capture can identify glycoproteins, which are indicative of different stages of prostate disease. By utilizing upfront lectin fractionation we show here evidence of glycoproteins and glycoprotein isoforms, which are specific to cancer progression. In addition, the incorporation of lectin fractionation followed by albumin depletion allows for a more in depth analysis of the entire dynamic range of the human serum and plasma proteome. Taken together we believe this approach is an attractive strategy for the discovery of proteins indicative of the early detection of liver and prostate cancers.
590 $a School code: 0418.
650 4 $a Biology, Molecular. $3 1017719
650 4 $a Health Sciences, Oncology. $3 1018566
690 $a 0307
690 $a 0992
710 2 0 $a Old Dominion University. $3 1020684
773 0 $t Dissertation Abstracts International $g 67-12B.
790 $a 0418
790 1 0 $a Drake, Richard, $e advisor
791 $a Ph.D.
792 $a 2006
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3246902